Compounds > tnp 351
Page last updated: 2024-12-11

tnp 351

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

TNP 351: a novel antifolate being evaluated for chemotherapy of lung cancer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5487322
SCHEMBL ID5300564
MeSH IDM0209445

Synonyms (19)

Synonym
tnp 351
(2s)-2-[[4-[3-(2,4-diamino-7h-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]amino]pentanedioic acid
l-glutamic acid, n-(4-(3-(2,4-diamino-1h-pyrrolo(2,3-d)pyrimidin-5-yl)propyl)benzoyl)-
48go5za420 ,
125991-51-7
tnp-351
n-(4-(3-(2,4-diamino-1h-pyrrolo(2,3-d)pyrimidin-5-yl)propyl)benzoyl)-l-glutamic acid
unii-48go5za420
n-(4-(3-(2,4-diamino-7h-pyrrolo(2,3-d)pyrimidin-5-yl)propyl)benzoyl)glutamic acid
l-glutamic acid, n-(4-(3-(2,4-diamino-7h-pyrrolo(2,3-d)pyrimidin-5-yl)propyl)benzoyl)-
SCHEMBL5300564
DTXSID30155032
n-{4-[3-(2,4-diamino-7h-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl}-l-glutamic acid
(4-(3-(2,4-diamino-1h-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)benzoyl)-l-glutamic acid
CS-0014801
Q27259143
HY-19095
l-glutamic acid, n-[4-[3-(2,4-diamino-7h-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-
AKOS040747542

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The test drug was used on dosage schedules of single and daily doses for 5 or 3 days (by intravenous drip over 30 minutes, respectively)."( [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Akazawa, S; Furue, H; Hasegawa, K; Kanamaru, R; Niitani, H; Sasaki, T; Taguchi, T; Tominaga, T; Tsukagoshi, S; Yoneda, S, 1995)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (87.50)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.87 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews2 (25.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (62.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
trimetrexate
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.		3.9920
cytarabine
[no description available]		3.0810beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.0110pyrrole;
secondary amine
deoxycytidine
[no description available]		3.0810pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		1.9810glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
methotrexate
[no description available]		6.4981dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
aminopterin
Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.		3.9920dicarboxylic acidEC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen
2'-deoxy-2'-methylenecytidine
[no description available]		3.0810
edatrexate
edatrexate: structure given in first source		3.9920glutamic acid derivative
guanine
[no description available]		2.01102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pemetrexed
pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).		2.0110N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		01.9810
Carcinoma, Non-Small Cell Lung
[description not available]		01.9810
Carcinoma, Epidermoid
[description not available]		01.9810
Cancer of Lung
[description not available]		05.241
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		01.9810
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		01.9810
Lung Neoplasms
Tumors or cancer of the LUNG.		05.241
Breast Cancer
[description not available]		03.3711
Cancer of Gastrointestinal Tract
[description not available]		03.3711
Mucositis, Oral
[description not available]		03.3711
Emesis
[description not available]		03.3711
Anorexia
The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.		03.3711
Breast Neoplasms
Tumors or cancer of the human BREAST.		03.3711
Stomatitis
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.		03.3711
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		03.3711
Leukemia, Lymphocytic
[description not available]		01.9810
Leukemia, Lymphoid
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.		01.9810
Leukemia L 1210
[description not available]		02.910
Carcinoma, Oat Cell
[description not available]		01.9910
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		01.9910